Local News
Adults from the area take part in a “game-changing” Alzheimer’s medication trial
Rochester, New York – A small group of local adults took part in a study for a brand-new Alzheimer’s medication.
Lecanemab, the medication, was evaluated in phase 3 international clinical trial. According to drug producers, a monoclonal antibody treatment for Alzheimer’s disease significantly delayed the rate of cognitive loss compared to a placebo.
This is a significant step towards postponing the disease’s consequences, according to Dr. Anton Porsteinsson, Director of the University of Rochester Alzheimer’s Disease Care.
“What the families say, I want to keep them the way they are now for as long as possible so that we can enjoy the time that we have together and delay the time until they need all of the constant supervision,” said Dr. Porsteinsson.
By the end of March 2023, the trial’s participating companies hope to receive regulatory approval from the United States.
-
New York2 weeks ago
Due to the bird flu, New York has added new, temporary regulations for the import of dairy cattle
-
Local News2 weeks ago
Friends and family assemble to honor the victim of the Driving Park Bridge hit-and-run
-
Local News5 days ago
The people of Rochester come together to honor Reverend Iris J. Banister’s life and legacy
-
Local News1 week ago
Former Rochester spa owner charged with leveraging company to engage in prostitution around WNY
-
Local News2 weeks ago
This weekend, there will be cleanup events in the Rochester region
-
Local News1 week ago
The Rochester Underground Railroad byway project’s first public meeting
-
Local News2 weeks ago
The first state-licensed cannabis shop opens in the City of Rochester
-
Local News1 week ago
Mayor outraged after judge releases suspect in city security guard’s baseball bat beating